Atlas Trials

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Clinical trial NCT02485015 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02485015
Sponsor
The First People's Hospital of Changzhou
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Stomach Neoplasms
Start date
2015-06-01
Primary completion
2030-06-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.